VIRALEZE antiviral nasal spray registered in Europe
Filed with ASX · · 3 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Starpharma signs DEP ADC Research Agreement with MSD
- AZD0466 clinical DEP program global expansion
- Change in substantial holding
- VIRALEZE COVID-19 nasal spray study to commence in January
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
Later from Starpharma
- DEP HER2-lutetium outperforms in human breast cancer model
- VIRALEZE to be launched with LloydsPharmacy in the UK
- VIRALEZE™ now launched by LloydsPharmacy in the UK
- VIRALEZE launches in Europe
- VIRALEZE SPL7013 highly active in UK variant of coronavirus
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma